U.S. stock night trading volatility: Alnylam Pharma's collaboration with PeptiDream boosts confidence, stock price rises 3% in night trading

U.S. Stock Market After-Hours Movements Alnylam Pharma rose 3% in after-hours trading. Based on recent key news: On December 19, Alnylam Pharma's collaboration agreement with PeptiDream had a positive impact. According to the agreement, PeptiDream will receive milestone payments from Alnylam and is eligible for additional development, regulatory, and commercial milestone payments, as well as low single-digit sales royalties. This collaboration has enhanced market confidence in Alnylam's future development, driving the stock price up. On December 21, market analysts rated Alnylam Pharma as "Moderate Buy," but it was not included in the top recommended stocks list. Nevertheless, the analysts' rating still reflects recognition of the company, supporting the rise in stock price. On December 19, Brown Advisory's investment strategy performed poorly, but Alnylam Pharma was unaffected. Despite Brown Advisory's strategy failing to outperform the benchmark, Alnylam Pharma's stock price continued to maintain an upward trend. The U.S. stock market has seen increased volatility recently, necessitating attention to risks. Stocks with High Trading Volume in the Industry Recursion Pharmaceuticals rose 3.05% in after-hours trading. Based on recent news: On December 19, Recursion Pharmaceuticals' CEO Christopher Gibson reported the sale of company common stock. This news may raise concerns in the market about confidence in the company's internal management, leading to stock price fluctuations. On December 19, ARKG and ARKK funds purchased 755,538 shares of Recursion Pharmaceuticals. This large-scale buying behavior demonstrates institutional investors' confidence in the company, driving the stock price up. On December 19, Brera Holdings' strategic acquisition actions sparked market interest in related biotech companies, indirectly boosting Recursion Pharmaceuticals' stock price. The biotech industry has been active recently, with significant capital inflows. Moderna rose 0.44% in after-hours trading. Based on recent key news: On December 19, CEPI announced an investment of up to $54.3 million to support Moderna's H5 influenza vaccine candidate's licensing process. This news boosted Moderna's stock price, indicating increased market confidence in the vaccine's development. On December 19, Moderna's mRNA technology achieved significant breakthroughs in cancer treatment, with research showing its targeting ability increased over a hundredfold, and the combined therapy's tumor suppression rate reached 93%. This research progress further enhanced market recognition of Moderna's technology, driving the stock price up On December 20, the United States adjusted its health policy, cutting funding for mRNA vaccines, which affected Moderna's market expectations. Nevertheless, Moderna's stock price continued to rise due to its technological breakthroughs. The mRNA technology breakthrough has garnered significant market attention. CRISPR Therapeutics rose 0.39%. Based on recent key news: On December 19, sales expectations for CRISPR Therapeutics' only approved therapy increased, potentially driving improvements in the company's performance. Analysts believe that the Casgevy therapy may break through in 2026, leading to significant revenue growth and enhancing the company's financial condition. Source: Benzinga On December 19, CRISPR Therapeutics was seen as a potential acquisition target. The company has approximately $2 billion in liquid assets and no long-term debt, attracting the attention of large medical companies. Source: Benzinga On December 19, market sentiment towards CRISPR Therapeutics became more optimistic. Analysts believe the company's business is heading in the right direction and recommend investors to pay attention. Source: Benzinga The healthcare industry focuses on innovative therapies, with significant capital inflow